Genetic Variants of EGFR (142285G>A) and ESR1 (2014G>A) Gene Polymorphisms and Risk of Breast Cancer

Overview

Journal Mol Cell Biochem

Publisher Springer

Specialty Biochemistry

Date 2012 Jul 20

PMID 22810499

Citations 4

Authors

Ranbir Chander Sobti

Marjan Askari

Mohsen Nikbakht

Neha Singh

Suresh C Sharma

Abayneh Munshea Abitew

Affiliations

Soon will be listed here.

Abstract

Breast cancer is one of the most common cancers in women worldwide. The estrogen receptor alpha (ESR1) and epidermal growth factor receptor (EGFR) have been known to play a vital role in development and progression of breast cancer. The aim of the present study was to determine the relationship, if any, between genetic polymorphism in (ESR1) 2014G>A (T594T) and (EGFR) 142285G>A (R521K) with risk of breast cancer and the prognosis in a heterogeneous North Indian population that is known for its diverse ethnicity. A case-control study in a total of 300 individuals comprising of 150 breast cancer patients and 150 normal controls was performed. PCR-RFLP was employed for genotyping. The G/A heterozygous genotype EGFR R521K, was slightly higher in cases (56.7 %) than in controls (48.3 %) (P = 0.20). The results indicated that EGFR polymorphism does not show any significant association with breast cancer in this population. On the other hand, the mutant A/A genotype ESR1 codon 594, showed a 6.4-folds risk for breast cancer and this association was highly significant (P = 0.00) as compared to wild GG genotype, the heterozygous G/A genotype also showed a significant association with disease (P = 0.00, OR = 2.03). In addition, the frequency of A allele was also higher in cases (36 %) than in controls (19 %) and a highly significant difference was observed with wild G allele (63.3 % in cases and 6.6 % in controls). This clearly indicates that there appears to be an influence of ESR1 codon 594 genotypes on genetic susceptibility to breast cancer. Further a significantly higher risk was observed in individuals who had diabetes {OR = 3.04 (1.68-5.50), P = 0.00} and females with ESR polymorphism in pre-menopause patients that had undergone menopause above the age of 50 years {OR = 3.58 (1.86-6.90), P < 0.05}. The different ethnic backgrounds and geographical locations have complimented the present genotypic analysis and have highlighted the influence of ethnicity, race and geographic location in genetic predisposition to breast cancer.

Citing Articles

The distribution pattern of ERα expression, ESR1 genetic variation and expression of growth factor receptors: association with breast cancer prognosis in Russian patients treated with adjuvant tamoxifen.

Babyshkina N, Vtorushin S, Zavyalova M, Patalyak S, Dronova T, Litviakov N Clin Exp Med. 2016; 17(3):383-393.

PMID: 27225751 DOI: 10.1007/s10238-016-0428-z.

A Meta-Analysis on the Relations between EGFR R521K Polymorphism and Risk of Cancer.

Wang Y, Zha L, Liao D, Li X Int J Genomics. 2014; 2014:312102.

PMID: 25401099 PMC: 4221867. DOI: 10.1155/2014/312102.

Epidermal growth factor receptor (EGFR) polymorphisms and breast cancer among Hispanic and non-Hispanic white women: the Breast Cancer Health Disparities Study.

Connor A, Baumgartner R, Baumgartner K, Pinkston C, John E, Torres-Mejia G Int J Mol Epidemiol Genet. 2013; 4(4):235-49.

PMID: 24319539 PMC: 3852643.

The polymorphism of EGFR 142285G > A exerts no risk effect on breast cancer.

Zheng Q, Chen R, Luan L, Li J, Gao S Tumour Biol. 2013; 35(3):2383-9.

PMID: 24163083 DOI: 10.1007/s13277-013-1315-9.

References

Michels K, Solomon C, Hu F, Rosner B, Hankinson S, Colditz G . Type 2 diabetes and subsequent incidence of breast cancer in the Nurses' Health Study. Diabetes Care. 2003; 26(6):1752-8. DOI: 10.2337/diacare.26.6.1752. View

Bianco R, Gelardi T, Damiano V, Ciardiello F, Tortora G . Rational bases for the development of EGFR inhibitors for cancer treatment. Int J Biochem Cell Biol. 2007; 39(7-8):1416-31. DOI: 10.1016/j.biocel.2007.05.008. View

Papadopoulou E, Simopoulos K, Tripsianis G, Tentes I, Anagnostopoulos K, Sivridis E . Allelic imbalance of HER-2 codon 655 polymorphism among different religious/ethnic populations of northern Greece and its association with the development and the malignant phenotype of breast cancer. Neoplasma. 2007; 54(5):365-73. View

Zhou Q, Cheung Y, Jada S, Lim W, Kuo W, Gray J . EGFR Intron 1 polymorphism in Asian Populations and its correlation with EGFR gene expression and amplification in breast tumor tissues. Cancer Biol Ther. 2006; 5(11):1445-9. DOI: 10.4161/cbt.5.11.3457. View

Hong Y, Deming S, Gao Y, Long J, Shu X, Cai Q . A two-stage case-control study of EGFR polymorphisms and breast cancer risk. Cancer Epidemiol Biomarkers Prev. 2009; 18(2):680-3. PMC: 2702716. DOI: 10.1158/1055-9965.EPI-08-0961. View

Zhang W, Stoehlmacher J, Park D, Yang D, Borchard E, Gil J . Gene polymorphisms of epidermal growth factor receptor and its downstream effector, interleukin-8, predict oxaliplatin efficacy in patients with advanced colorectal cancer. Clin Colorectal Cancer. 2005; 5(2):124-31. DOI: 10.3816/ccc.2005.n.025. View

Weber B, Nathanson K . Low penetrance genes associated with increased risk for breast cancer. Eur J Cancer. 2000; 36(10):1193-9. DOI: 10.1016/s0959-8049(00)00082-4. View

. Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. Lancet. 2001; 358(9291):1389-99. DOI: 10.1016/S0140-6736(01)06524-2. View

Pham D, Kris M, Riely G, Sarkaria I, McDonough T, Chuai S . Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas. J Clin Oncol. 2006; 24(11):1700-4. DOI: 10.1200/JCO.2005.04.3224. View

10.

Kang H, Kim S, Kim H, Ahn S, Bae J, Park S . Polymorphisms in the estrogen receptor-alpha gene and breast cancer risk. Cancer Lett. 2002; 178(2):175-80. DOI: 10.1016/s0304-3835(01)00861-8. View

11.

Cappuzzo F, Hirsch F, Rossi E, Bartolini S, Ceresoli G, Bemis L . Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst. 2005; 97(9):643-55. DOI: 10.1093/jnci/dji112. View

12.

Houlston R, Tomlinson I . Detecting low penetrance genes in cancer: the way ahead. J Med Genet. 2000; 37(3):161-7. PMC: 1734538. DOI: 10.1136/jmg.37.3.161. View

13.

Narod S . Modifiers of risk of hereditary breast and ovarian cancer. Nat Rev Cancer. 2003; 2(2):113-23. DOI: 10.1038/nrc726. View

14.

ODriscoll L, Clynes M . Biomarkers and multiple drug resistance in breast cancer. Curr Cancer Drug Targets. 2006; 6(5):365-84. DOI: 10.2174/156800906777723958. View

15.

Mason R, Morlock E, Karagas M, Kelsey K, Marsit C, Schned A . EGFR pathway polymorphisms and bladder cancer susceptibility and prognosis. Carcinogenesis. 2009; 30(7):1155-60. PMC: 2704279. DOI: 10.1093/carcin/bgp077. View

16.

Larsson S, Mantzoros C, Wolk A . Diabetes mellitus and risk of breast cancer: a meta-analysis. Int J Cancer. 2007; 121(4):856-62. DOI: 10.1002/ijc.22717. View

17.

Olayioye M, Neve R, Lane H, Hynes N . The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J. 2000; 19(13):3159-67. PMC: 313958. DOI: 10.1093/emboj/19.13.3159. View

18.

Lehrer S, Levine E, Savoretti P, Cropley J, Thung S, Song H . Oestrogen and progesterone receptor dissociation and family history of breast cancer. Lancet. 1992; 339(8801):1108-9. DOI: 10.1016/0140-6736(92)90697-2. View

19.

Nomura M, Shigematsu H, Li L, Suzuki M, Takahashi T, Estess P . Polymorphisms, mutations, and amplification of the EGFR gene in non-small cell lung cancers. PLoS Med. 2007; 4(4):e125. PMC: 1876407. DOI: 10.1371/journal.pmed.0040125. View

20.

Murthy N, Chaudhry K, Nadayil D, Agarwal U, Saxena S . Changing trends in incidence of breast cancer: Indian scenario. Indian J Cancer. 2009; 46(1):73-4. DOI: 10.4103/0019-509x.48603. View